CL2020000556A1 - Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvirus ovis (ppvo) y al menos un fármaco antivírico adicional. - Google Patents

Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvirus ovis (ppvo) y al menos un fármaco antivírico adicional.

Info

Publication number
CL2020000556A1
CL2020000556A1 CL2020000556A CL2020000556A CL2020000556A1 CL 2020000556 A1 CL2020000556 A1 CL 2020000556A1 CL 2020000556 A CL2020000556 A CL 2020000556A CL 2020000556 A CL2020000556 A CL 2020000556A CL 2020000556 A1 CL2020000556 A1 CL 2020000556A1
Authority
CL
Chile
Prior art keywords
ppvo
combination therapies
hepatitis
virus
infected individuals
Prior art date
Application number
CL2020000556A
Other languages
English (en)
Inventor
Daniela Paulsen
Andreas Urban
Ibironke Addy
Tamara Pfaff
Stephan Menne
Willem Sloot
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of CL2020000556A1 publication Critical patent/CL2020000556A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A NUEVAS TERAPIAS DE COMBINACIÓN DE INDIVIDUOS INFECTADOS CON VHB USANDO UN PARAPOXVIRUS OVIS (PPVO) Y AL MENOS UN FÁRMACO ANTIVÍRICO ADICIONAL, POR EJEMPLO, INHIBIDORES DE NUCLEÓSIDO, TALES COMO ENTECAVIR. LOS MÉTODOS Y LOS PRODUCTOS DE COMBINACIÓN DE ACUERDO CON LA PRESENTE INVENCIÓN SON SEGUROS Y ADECUADOS PARA LA INDUCCIÓN DE UNA CURA FUNCIONAL EN PACIENTES CRÓNICAMENTE INFECTADOS CON VHB.
CL2020000556A 2017-09-07 2020-03-05 Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvirus ovis (ppvo) y al menos un fármaco antivírico adicional. CL2020000556A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189890 2017-09-07
EP17196684 2017-10-16

Publications (1)

Publication Number Publication Date
CL2020000556A1 true CL2020000556A1 (es) 2020-09-04

Family

ID=63442656

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000556A CL2020000556A1 (es) 2017-09-07 2020-03-05 Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvirus ovis (ppvo) y al menos un fármaco antivírico adicional.

Country Status (20)

Country Link
US (1) US20200261520A1 (es)
EP (1) EP3678697A1 (es)
JP (2) JP2020533314A (es)
KR (1) KR20200051685A (es)
CN (1) CN111093697A (es)
AU (1) AU2018327688B2 (es)
BR (1) BR112020004539A2 (es)
CA (1) CA3075206A1 (es)
CL (1) CL2020000556A1 (es)
CU (1) CU20200016A7 (es)
EC (1) ECSP20016672A (es)
GE (1) GEP20237518B (es)
IL (1) IL273093A (es)
MA (1) MA50071A (es)
MX (1) MX2020002605A (es)
PH (1) PH12020500445A1 (es)
SG (1) SG11202001931WA (es)
TW (1) TW201919675A (es)
UY (1) UY37869A (es)
WO (1) WO2019048640A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3906929A1 (en) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir for use in the prevention and the treatment of coronavirus infections
SI3906970T1 (sl) 2020-05-08 2022-11-30 Aicuris Gmbh & Co. Kg Parapoksvirus za kondicioniranje in zdravljenje koronavirusnih okužb
EP4157327A1 (en) * 2020-05-28 2023-04-05 The Regents Of The University Of Michigan Compositions and methods for preventing and treating sars-cov-2 infection
WO2023083943A1 (en) 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals
WO2023083950A1 (en) 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators
WO2023083951A1 (en) 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory syncytial virus infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL153826A0 (en) * 2000-07-11 2003-07-31 Bayer Ag Use of strains of the parapox ovis virus against organ fibrosis
EP1303286B1 (de) * 2000-07-11 2006-04-26 Bayer HealthCare AG Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs
PL1765370T3 (pl) * 2004-07-13 2010-02-26 Aicuris Gmbh & Co Kg Parapoksywirusy w kombinacji z innymi czynnikami przeciwwirusowymi do leczenia HIV/AIDS
WO2007068380A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl urea for treating virus infections
JP5699093B2 (ja) * 2012-01-05 2015-04-08 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＡｉＣｕｒｉｓ ＧｍｂＨ ＆ Ｃｏ． ＫＧ パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
WO2017015451A1 (en) * 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents

Also Published As

Publication number Publication date
UY37869A (es) 2019-04-30
JP2022167901A (ja) 2022-11-04
SG11202001931WA (en) 2020-04-29
IL273093A (en) 2020-04-30
CU20200016A7 (es) 2020-11-30
PH12020500445A1 (en) 2020-11-09
KR20200051685A (ko) 2020-05-13
AU2018327688B2 (en) 2022-12-01
MX2020002605A (es) 2020-07-20
AU2018327688A1 (en) 2020-03-19
ECSP20016672A (es) 2020-06-30
MA50071A (fr) 2020-07-15
BR112020004539A2 (pt) 2020-09-08
US20200261520A1 (en) 2020-08-20
CN111093697A (zh) 2020-05-01
WO2019048640A1 (en) 2019-03-14
EP3678697A1 (en) 2020-07-15
GEP20237518B (en) 2023-07-10
CA3075206A1 (en) 2019-03-14
TW201919675A (zh) 2019-06-01
JP2020533314A (ja) 2020-11-19

Similar Documents

Publication Publication Date Title
CL2020000556A1 (es) Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvirus ovis (ppvo) y al menos un fármaco antivírico adicional.
DOP2018000074A (es) Moduladores de la proteína core de la hepatitis b
CL2018002549A1 (es) Eliminación del virus de la hepatitis b con agentes antivirales
CL2018002528A1 (es) Agentes anti virales de la hepatitis b.
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
ECSP18069924A (es) Compuestos tetracíclicos de piridona como antivirales
CR20170424A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CR20170174A (es) Composiciones y métodos para el silenciamiento de la expresión cénica del virus de la hepatitis b
CL2015001971A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas.
BR112019004560A2 (pt) tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv
EA201790160A1 (ru) Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d
CY1120158T1 (el) Γλουταρυλο ισταμινη για την αγωγη και προφυλαξη παθησεων προκαλουμενων απο ιους που περιεχουν (+)rna
MX2017009812A (es) Composiciones y metodos para inhibir infeccion viral.
BR112015026243A2 (pt) método de inibição viral
CO2017005767A2 (es) Composiciones de acción prolongada de combinación y procedimientos para hepatitis c
CO2017005766A2 (es) Composiciones farmacéuticas de acción prolongada para hepatitis c
EA201590297A1 (ru) Гетероциклические карбоксамиды для лечения вирусных заболеваний
EA202090597A1 (ru) Комбинированная терапия пациентов, инфицированных вирусом гепатита в (hbv), с использованием parapoxvirus ovis (ppvo) и по меньшей мере одного дополнительного противовирусного средства
MX2018000213A (es) Metodos para tratar el vhc.
AR105611A1 (es) TERAPIA ARNi PARA INFECCIÓN POR VIRUS DE HEPATITIS B
EA201691835A1 (ru) Аллостерические модуляторы капсидного белка гепатита в
UA84300U (ru) Способ иммунокоррекции взрослых больных вирусным гепатитом а